Alice Y Chan1,2, Troy R Torgerson3. 1. Division of Pediatric Allergy, Immunology, and BMT. 2. Division of Pediatric Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, California. 3. Allen Institute for Immunology and Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: Primary immune regulatory disorders (PIRD) are a growing subset of diseases referred to as inborn errors of immunity. Unlike classical primary immune deficiency disorders that typically present with severe, recurrent, or unusual infections, the clinical manifestations of PIRD are dominated by immune-mediated diseases (autoimmunity, autoinflammation/hyperinflammation, lymphoproliferation, malignancy, and severe atopy). This review introduces the concept of PIRD including clinical phenotypes, treatments, and new PIRD-associated gene defects. RECENT FINDINGS: The number of genetic defects associated with PIRD is rapidly growing. The identified genes often encode proteins that play critical roles in regulating the immune response to various triggers. Understanding the molecular mechanisms underlying PIRD has shed light on the clinical phenotypes and has helped to identify targeted therapies. In some cases, hematopoietic cell transplant (HCT) has been successfully employed as a cure. SUMMARY: It is important to recognize the broad clinical manifestations of PIRD as patients may have symptoms atypical of classical 'immunodeficiency'. Because of their diverse immune dysregulation problems, they are often primarily managed by other subspecialists. Immunologists can help connect the diverse immune-mediated pathologies to a gene defect. This, in turn, can play a significant role in directing clinical management, selecting effective therapy, and deciding on appropriateness of HCT.
PURPOSE OF REVIEW: Primary immune regulatory disorders (PIRD) are a growing subset of diseases referred to as inborn errors of immunity. Unlike classical primary immune deficiency disorders that typically present with severe, recurrent, or unusual infections, the clinical manifestations of PIRD are dominated by immune-mediated diseases (autoimmunity, autoinflammation/hyperinflammation, lymphoproliferation, malignancy, and severe atopy). This review introduces the concept of PIRD including clinical phenotypes, treatments, and new PIRD-associated gene defects. RECENT FINDINGS: The number of genetic defects associated with PIRD is rapidly growing. The identified genes often encode proteins that play critical roles in regulating the immune response to various triggers. Understanding the molecular mechanisms underlying PIRD has shed light on the clinical phenotypes and has helped to identify targeted therapies. In some cases, hematopoietic cell transplant (HCT) has been successfully employed as a cure. SUMMARY: It is important to recognize the broad clinical manifestations of PIRD as patients may have symptoms atypical of classical 'immunodeficiency'. Because of their diverse immune dysregulation problems, they are often primarily managed by other subspecialists. Immunologists can help connect the diverse immune-mediated pathologies to a gene defect. This, in turn, can play a significant role in directing clinical management, selecting effective therapy, and deciding on appropriateness of HCT.
Authors: Judith R Kelsen; Kathleen E Sullivan; Shervin Rabizadeh; Namita Singh; Scott Snapper; Abdul Elkadri; Andrew B Grossman Journal: J Pediatr Gastroenterol Nutr Date: 2020-03 Impact factor: 2.839
Authors: Katja G Weinacht; Louis-Marie Charbonnier; Fayhan Alroqi; Ashley Plant; Qi Qiao; Hao Wu; Clement Ma; Troy R Torgerson; Sergio D Rosenzweig; Thomas A Fleisher; Luigi D Notarangelo; Imelda C Hanson; Lisa R Forbes; Talal A Chatila Journal: J Allergy Clin Immunol Date: 2017-01-27 Impact factor: 10.793
Authors: Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper Journal: J Allergy Clin Immunol Pract Date: 2016 Nov - Dec
Authors: Mohammed F Alosaimi; Manfred Hoenig; Faris Jaber; Craig D Platt; Jennifer Jones; Jacqueline Wallace; Klaus-Michael Debatin; Ansgar Schulz; Eva Jacobsen; Peter Möller; Hanan E Shamseldin; Ferdous Abdulwahab; Niema Ibrahim; Hosam Alardati; Faisal Almuhizi; Ibraheem F Abosoudah; Talal A Basha; Janet Chou; Fowzan S Alkuraya; Raif S Geha Journal: J Allergy Clin Immunol Date: 2019-03-11 Impact factor: 10.793
Authors: Sarah A Cook; William A Comrie; M Cecilia Poli; Morgan Similuk; Andrew J Oler; Aiman J Faruqi; Douglas B Kuhns; Sheng Yang; Alexander Vargas-Hernández; Alexandre F Carisey; Benjamin Fournier; D Eric Anderson; Susan Price; Margery Smelkinson; Wadih Abou Chahla; Lisa R Forbes; Emily M Mace; Tram N Cao; Zeynep H Coban-Akdemir; Shalini N Jhangiani; Donna M Muzny; Richard A Gibbs; James R Lupski; Jordan S Orange; Geoffrey D E Cuvelier; Moza Al Hassani; Nawal Al Kaabi; Zain Al Yafei; Soma Jyonouchi; Nikita Raje; Jason W Caldwell; Yanping Huang; Janis K Burkhardt; Sylvain Latour; Baoyu Chen; Gehad ElGhazali; V Koneti Rao; Ivan K Chinn; Michael J Lenardo Journal: Science Date: 2020-07-10 Impact factor: 47.728
Authors: Alice Y Chan; Jennifer W Leiding; Xuerong Liu; Brent R Logan; Lauri M Burroughs; Eric J Allenspach; Suzanne Skoda-Smith; Gulbu Uzel; Luigi D Notarangelo; Mary Slatter; Andrew R Gennery; Angela R Smith; Sung-Yun Pai; Michael B Jordan; Rebecca A Marsh; Morton J Cowan; Christopher C Dvorak; John A Craddock; Susan E Prockop; Shanmuganathan Chandrakasan; Neena Kapoor; Rebecca H Buckley; Suhag Parikh; Deepak Chellapandian; Benjamin R Oshrine; Jeffrey J Bednarski; Megan A Cooper; Shalini Shenoy; Blachy J Davila Saldana; Lisa R Forbes; Caridad Martinez; Elie Haddad; David C Shyr; Karin Chen; Kathleen E Sullivan; Jennifer Heimall; Nicola Wright; Monica Bhatia; Geoffrey D E Cuvelier; Frederick D Goldman; Isabelle Meyts; Holly K Miller; Markus G Seidel; Mark T Vander Lugt; Rosa Bacchetta; Katja G Weinacht; Jeffrey R Andolina; Emi Caywood; Hey Chong; Maria Teresa de la Morena; Victor M Aquino; Evan Shereck; Jolan E Walter; Morna J Dorsey; Christine M Seroogy; Linda M Griffith; Donald B Kohn; Jennifer M Puck; Michael A Pulsipher; Troy R Torgerson Journal: Front Immunol Date: 2020-02-21 Impact factor: 7.561